title: [Pharmacokinetics of cefmenoxime in renal-failure patients undergoing continuous arteriovenous hemofiltration].
abstract: We investigated the pharmacokinetics of cefmenoxime (CMX) administrated to renal-failure patients undergoing continuous arteriovenous hemofiltration (CAVH). CAVH was carried out with a filter (0.5 m2) employing a PAN-50P (hollow fiber type) made of polyacrylonitrile membrane, with a blood flow rate of 100 ml/min and a filtration rate of 1,200 ml/hr. At 5 and 300 minutes after the CMX administration, the concentrations of CMX in the serum were 126.8 mg/L and 31.5 mg/L, respectively. The T1/2 beta was 3.55 hours. In 300 minutes after the administration of CMX, the total amount of CMX contained in the filtrate corresponded to 11.6% of the administered dose.
authors.affiliation: Third Department of Internal Medicine, Kinki University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Hasegawa
authors.forename: N
authors.initials: N
authors.lastname: Itagaki
authors.forename: M
authors.initials: M
authors.lastname: Tsujino
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: A
authors.initials: A
authors.lastname: Imada
authors.forename: A
authors.initials: A
authors.lastname: Horiuchi
mesh_terms: D058186:Acute Kidney Injury / Q000378:metabolism* / Q000628:therapy; D000328:Adult; D000368:Aged; D015281:Cefmenoxime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006440:Hemofiltration; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
chemical_list: D015281:Cefmenoxime; D002439:Cefotaxime